Business introduction - Vaccine Bio Research Institute, the Catholic University of Korea

MISSION

VRIC aims to identify unmet medical needs for infectious disease vaccines and biomarkers and conduct translational research through a multi-center/multidisciplinary platform.

Functioning as the central laboratory for clinical trials and collaborating with international organizations
Ensuring self-sufficiency and globalization of domestic vaccines and expanding the role of the Ministry of Food and Drug Safety clinical trial specimen analysis institute
Providing and serving as a focal point for infectious disease-related industry, academia, hospitals, and research-associated platform
Bacterial, fungal, and viral domestic molecular epidemiology and pathogenesis
Developing early diagnostic systems using biomarkers and conducting research on source technologies for treatment
Leading the clinical application and commercialization of the cutting edge diagnostic and therapeutic technologies for infectious diseases, including advanced regenerative medicine

Vaccine-Bio Research Institute,
Catholic University of Korea (VRIC)

Vaccine technology development (self-sufficiency)
and vaccine standardization projects
Designing clinical trials

Vaccine development and evaluation, diagnostic biomarker and infectious disease therapeutic clinical trials
Rich infectious disease-based clinical experience

Early identification of unmet medical needs
Research on industrialization of infectious disease response technology and the development of biomarkers and diagnostic kits
Analyzing clinical trial samples

Evaluating clinical validity and performance of developed vaccines and diagnostic biomarkers (immunogenicity, sensitivity, specificity, etc.)
Multilateral (global) collaboration-based infectious disease response technology development platform

Establishing global partnerships to develop medical technologies for unmet medical needs in collaboration with other research organizations, such as the International Vaccine Institute

GCP - Good Clinical Practice, GCLP - Good Clinical Laboratory Practice

VRIC - Vaccine Bio Research Institute, the Catholic University of Korea

Designing clinical trial technologies

Accumulating skills in clinically-based translational research

Experience in infectious disease clinical and non-clinical research (new drugs, vaccines, etc.)
Accumulating clinical information on infectious diseases
Reflecting the needs of the field (bottom-up)

Infectious disease response technology platform

Network-based labor pool of infection specialists
Emerging/variant pathogen analysis
Antimicrobial resistance (AMR) research
Resistance and virulence gene analysis

Clinical basic translational research

GCLP for vaccine standardization/vaccine

Clinical research collaborations
Evaluating vaccine efficacy in development
GCLP designated by the Ministry of Food and Drug Safety
Central lab of the International Vaccine Institute

Developing clinically relevant biomarkers

Developing diagnostic and therapeutic biomarkers
Development projects in collaboration with institutions such as POSTECH, KAIST, KIST, etc.
Providing a clinical simulation environment for diagnostic technology development
Clinical evaluation of developed diagnostic technologies

Building a support system for vaccine development, evaluation, and clinical trials
(2011-present, 42 projects, KRW 12,237,000,000)

Vaccine-based technology and standardization (GLP)
Clinical trial evaluation infrastructure for the developed vaccine (GCLP)

Vaccine standardization projects
- International standardization development research
- Non-clinical models for evaluating vaccine technologies
- Standardizing immunogenicity evaluation methods
Evaluating vaccine clinical trials
- Analyzing clinical trials of locally developed vaccines
- Developing and evaluating clinical trial immunogenicity assay protocols
Building a support system for clinical trials
- Multicenter clinical trial Infrastructure
- Clinical support for new vaccine development
- Accelerating development of new infectious disease drugs

Infectious disease-based research and biomarker development
(2011-present, 48 projects totaling KRW 4,394,222,000)

Providing a clinical simulation environment for biomarker development
Clinical evaluation of developed diagnostic technologies

Basic research and evaluation sample development
- Infectious disease basic research
- Development system management substances
- SL 2/3 qualitative/quantitative control group
- Clinical specimen utilization simulation
Clinically relevant biomarker validation technologies
- Biomarker validation clinical specimen collection
- Biomarker clinical protocol development
Evaluating development system clinical trials
- Analytic performance evaluation
- Validating comparative correlation
- Develop biomarker-enabled diagnostic and treatment algorithms

Clinically-based collaborative networks

Infectious diseases (8 CMC hospitals)
Laboratory medicine
Hematology
Respiratory medicine

External cooperation research institutes and government-contributed agencies

International Vaccine Institute, under the WHO
Ministry of Food and Korea Disease Control and Prevention Agency
Korea Health Industry Development Institute, National Research Foundation,
pan-ministerial full cycle research initiatives, etc.

Research collaborations with other universities, and pharmaceutical and diagnostic companies

Research collaborations

KAIST, KIST
POSTECH, Korea University
Kwangwoon University, Chungnam National University, etc.

Basic medical sciences laboratories and research institutes

Microbiology lab
Pharmacology lab
Biochemistry lab

Diagnosis and treatment

Lucas Bio
Connectagen
Pepxgen

Vaccine-Bio Research Institute, Catholic University of Korea NOW

Introduce